A multicenter clinical study of romiplostim N01 in the treatment of sepsis-related thrombocytopenia

INTERVENTION: control group:recombinant human thrombopoietin;treatment group:Romiplostim? N01; CONDITION: Sepsis‐associated thrombocytopenia (SAT) PRIMARY OUTCOME: The effective rate of platelet‐stimulating treatment after the 7th day; SECONDARY OUTCOME: Platelet counts on the 3rd day, 7th day, 9th day, and 14th day;The incidence of bleeding events after treatment;Length of stay in the ICU;The mortality rate 28 days after treatment;The time when platelet count first returned to = 100×10^9/L; INCLUSION CRITERIA: 1. Age >= 18 years old, gender unrestricted. 2. Meeting the diagnostic criteria of sepsis 3.0, namely: (1) Confirmed or suspected infection; (2) Organ dysfunction caused by infection, that is, Sequential Organ Failure Assessment (SOFA) score >= 2 points. If organ dysfunction is known to exist before infection, that is, the SOFA score is greater than 0 points, then the SOFA score must increase by >= 2 points after the infection occurs. 3. Platelet count <= 50 X10^9/L. 4. The subjects must fully understand and be able to comply with the requirements of the research protocol, and voluntarily sign the informed consent form.